Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=26082619
&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215
Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 245.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Deprecated: Implicit conversion from float 245.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\26082619
.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117 Drug+Des+Devel+Ther
2015 ; 9
(ä): 2919-25
Nephropedia Template TP
gab.com Text
Twit Text FOAVip
Twit Text #
English Wikipedia
Profile of ceftolozane/tazobactam and its potential in the treatment of
complicated intra-abdominal infections
#MMPMID26082619
Skalweit MJ
Drug Des Devel Ther
2015[]; 9
(ä): 2919-25
PMID26082619
show ga
Drug-resistant pathogens have gained a foothold especially in the most vulnerable
patient populations, hospitalized and immunocompromised individuals. Furthermore,
extended-spectrum ?-lactamase and carbapenemase-producing organisms are finding
their way even into the community, with patients presenting to the hospital with
established colonization and infection with resistant Enterobacteriaceae in
particular. Recently, a novel antipseudomonal cephalosporin in combination with
an established Class A ?-lactamase inhibitor, ceftolozane/tazobactam has been
approved by the FDA for use in the treatment of complicated urinary tract
infections and complicated intra-abdominal infections. Ceftolozane is a uniquely
potent antipseudomonal cephalosporin because of its high affinity for the
penicillin-binding proteins of Pseudomonas aeruginosa, its low affinity for the
intrinsic Class C ?-lactamases of P. aeruginosa, its ability to enter P.
aeruginosa through the outer membrane without the utilization of OprD protein,
and the fact that it is not a substrate of the often upregulated MexAB/OprM
efflux system of P. aeruginosa. The biological chemistry,
pharmacokinetics/pharmacodynamics, microbiologic spectrum, and clinical trials
that led to the approval of ceftolozane is reviewed. A discussion regarding its
potential role in the treatment of complicated intra-abdominal infections and
other infectious disease syndromes associated with drug-resistant pathogens
follows.